Effects of Dapagliflozin on Renal Function and Metabolic Outcomes in CKD Patients with Type 2 Diabetes | ||||
| The Medical Journal of Cairo University | ||||
| Volume 93, Issue 06, June 2025, Page 699-706 PDF (227.55 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2025.444576 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| RAMY IBRAHIM ELWARAKY, M.Sc.*; AMIRA B. KASSEM, Ph.D.*; AHMED FATHI ELKERAIE, M.D.**; GAMAL ABDELHAY OMRAN, Ph.D.*** and NOHA A. EL-BASSIOUNY, Ph.D.* | ||||
| The Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, Damanhour University*, Department of Internal Medicine & Nephrology, Faculty of Medicine, Alexandria University** and Department of Biochemistry, Faculty of Pharmacy, Damanhour University*** | ||||
| Abstract | ||||
| Background: Chronic kidney disease (CKD) in type 2 dia-betes mellitus (T2DM) is associated with metabolic, cardiovas-cular, and renal complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors like dapagliflozin offer benefits across these domains. Aim of Study: This study aims to evaluate the effects of dapagliflozin on renal function, glycemic control, body compo-sition, and blood pressure in CKD patients with T2DM, with a focus on changes in estimated glomerular filtration rate (eGFR), body mass index (BMI), and glycated hemoglobin (HbA1c). Patients and Methods: This prospective cohort study (March 2021–August 2024) included CKD patients with T2DM receiving dapagliflozin or other antidiabetic agents. Changes in eGFR, BMI, HbA1c, and blood pressure were assessed. Results: Among 255 patients (dapagliflozin: 155, con-trol: 100), eGFR decline was similar (–2.34 vs. –2.14mL/min; p=0.76). BMI (–1.05 vs. –0.13kg/m2, p<0.001) and HbA1c (–0.89% vs. –0.57%, p=0.008) decreased more with dapagli-flozin. Linear regression showed dapagliflozin did not signif-icantly affect systolic (p=0.282) or diastolic (p=0.610) blood pressure. Adverse events were comparable. Conclusions: Dapagliflozin improved BMI and HbA1c without significant effects on eGFR or blood pressure over 12-months of follow-up, and had an acceptable safety profile, supporting its role in CKD management in T2DM. | ||||
| Keywords | ||||
| Dapagliflozin; CKD Patients; T2 DM; SGLT2 | ||||
|
Statistics Article View: 107 PDF Download: 52 |
||||
